Zinger Key Points
- Medpace beats analyst estimates on the top and bottom lines in the first quarter.
- New business awards total $500 million in the quarter, down 18.8% year-over-year.
- China’s new tariffs just reignited the same market patterns that led to triple- and quadruple-digit wins for Matt Maley. Get the next trade alert free.
Medpace Holdings Inc MEDP reported first-quarter financial results after market close on Monday. Here’s a look at the key metrics from the quarter.
- Q1 Revenue: $558.57 million, versus estimates of $527.15 million
- Q1 EPS: $3.67, versus estimates of $3.06
Total revenue was up 9.3% on a year-over-year basis. New business awards totaled $500 million in the quarter, down 18.8% year-over-year. The company ended the period with a backlog of approximately $2.85 billion, down 2.1% year-over-year.
Medpace generated $125.8 million in cash flow from operations during the quarter. The company said it repurchased approximately 1.19 million shares for $389.8 million in the first quarter. Medpace’s board also authorized a $1 billion increase to the company’s buyback, bringing the total authorization up to approximately $1.34 billion.
The company ended the quarter with $441.4 million in cash and cash equivalents.
Outlook: Medpace expects full-year 2025 revenue to be between $2.14 billion and $2.24 billion versus estimates of $2.15 billion. The company anticipates full-year earnings of $12.26 to $13.04 per share versus estimates of $12.27 per share.
Medpace executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 9 a.m. ET.
MEDP Price Action: Medpace shares were down 9.34% after-hours, trading at $262 at the time of publication Monday, according to Benzinga Pro.
Check This Out:
• Calix Stock Jumps On Strong Q1 Earnings, $100 Million Buyback Increase
Photo: mariakray/Shutterstock.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.